Targeting AML-associated FLT3 mutations with a type I kinase inhibitor

Tyrosine kinase domain (TKD) mutations contribute to acquired resistance to FMS-like tyrosine kinase 3 (FLT3) inhibitors used to treat FLT3-mutant acute myeloid leukemia (AML). We report a cocrystal structure of FLT3 with a type I inhibitor, NCGC1481, that retained potent binding and activity agains...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Invest
Main Authors: Jones, LaQuita M., Melgar, Katelyn, Bolanos, Lyndsey, Hueneman, Kathleen, Walker, Morgan M., Jiang, Jian-Kang, Wilson, Kelli M., Zhang, Xiaohu, Shen, Jian, Jiang, Fan, Sutter, Patrick, Wang, Amy, Xu, Xin, Tawa, Gregory J., Hoyt, Scott B., Wunderlich, Mark, O’Brien, Eric, Perentesis, John P., Starczynowski, Daniel T., Thomas, Craig J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2020
Assuntos:
Concise Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7108888/
https://ncbi.nlm.nih.gov/pubmed/32149729
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI127907
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados